Dr. Joe Goldberg gathered the latest evidence on antidepressants in bipolar disorder at the 9th annual Mood Disorders Summit, and we summarize his findings.
Texas state legislators recently passed a bill that will greatly reduce the prior authorization workload. Will this open the door to the rest of the country?
Does the limited research support that oxcarbazepine is a safer and more effective treatment for bipolar disorder than its FDA-approved cousin, carbamazepine? Here is an overview of the pros and cons from a previous article in The Carlat Psychiatry Report.Pros:Similar effectiveness as other mood stabilizers. In mania and mixed states,...
Which antipsychotics should we consider selecting as the first-line and second-line treatments, and what should we base this decision on? Dr. Aziz addresses this in a past article from The Carlat Psychiatry Report. Here’s some of his advice:Process: Tolerability instead of efficacy should be considered when selecting a first-line treatment.
Ketamine and esketamine have been shown to provide rapid relief of suicidality, however, many lingering doubts have been raised about these medicines. In a previous article from The Carlat Psychiatry Report, Nolan Williams, M.D., discusses the potential negative consequences of ketamine/esketamine treatment. Here are some of Dr. Williams’s tips:It might...
Take a look around. See the new webinars. Try searching for a medication. Visit your new account page to see see your subscriptions and purchased materials.
